Standard BioTools Inc (NASDAQ:LAB) has a beta value of 1.55 and has seen 3.71 million shares traded in the last trading session. The company, currently valued at $431.82M, closed the last trade at $1.16 per share which meant it gained $0.03 on the day or 2.65% during that session. The LAB stock price is -162.07% off its 52-week high price of $3.04 and 14.66% above the 52-week low of $0.99.
The consensus among analysts is that Standard BioTools Inc (LAB) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
Standard BioTools Inc (NASDAQ:LAB) trade information
Sporting 2.65% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LAB stock price touched $1.16 or saw a rise of 5.69%. Year-to-date, Standard BioTools Inc shares have moved -33.71%, while the 5-day performance has seen it change 8.92%. Over the past 30 days, the shares of Standard BioTools Inc (NASDAQ:LAB) have changed -23.18%.
Wall Street analysts have a consensus price target for the stock at $3.25, which means that the shares’ value could jump 64.31% from current levels. The projected low price target is $3.25 while the price target rests at a high of $3.25. In that case, then, we find that the current price level is -180.17% off the targeted high while a plunge would see the stock gain -180.17% from current levels.
Standard BioTools Inc (LAB) estimates and forecasts
The company’s shares have lost -39.90% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -3.00%.
3 analysts offering their estimates for the company have set an average revenue estimate of 40.1M for the current quarter. 3 have an estimated revenue figure of 39.23M for the next ending quarter. Year-ago sales stood 45.54M and 37.2M respectively for this quarter and the next, and analysts expect sales will shrink by -11.95% for the current quarter and -3.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.58% over the past 5 years. Earnings growth for 2025 is a modest 65.38% while over the next 5 years, the company’s earnings are expected to increase by 57.47%.
LAB Dividends
Standard BioTools Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
The top two institutional holders are CASDIN CAPITAL, LLC with over 63.96 million shares worth more than $113.21 million. As of 2024-06-30, CASDIN CAPITAL, LLC held 17.1782% of shares outstanding.
The other major institutional holder is VIKING GLOBAL INVESTORS LP, with the holding of over 58.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $103.81 million and represent 15.7524% of shares outstanding.
